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ABSTRACT
Zinc is an essential micronutrient associated with over 300 biological functions.  Marginal zinc deficiency 
states are common among children living in poverty and exposed to diets either low in zinc or high in 
phytates that compromise zinc uptake. These children are at increased risk of morbidity due to infectious 
diseases, including diarrhoea and respiratory infection. Children aged less than five years (under-five chil-
dren) and those exposed to zinc-deficient diets will benefit from either daily supplementation of zinc or 
a 10 to 14-day course of zinc treatment for an episode of acute diarrhoea. This includes less severe illness 
and a reduced likelihood of repeat episodes of diarrhoea. Given these findings, the World Health Organiza-
tion/United Nations Children’s Fund now recommend that all children with an acute diarrhoeal illness be 
treated with zinc, regardless of aetiology. ICDDR.B scientists have led the way in identifying the benefits of 
zinc. Now, in partnership with the Ministry of Health and Family Welfare, Government of Bangladesh and 
the private sector, the first national scaling up of zinc treatment has been carried out. Important challenges 
remain in terms of reaching the poorest families and those living in remote areas of Bangladesh.
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INTRODUCTION
It is now over a decade since the publication of the 
landmark articles by Sazawal et al. and Roy et al. 
which demonstrated the efficacy of orally-adminis-
tered zinc in the treatment of acute childhood diar-
rhoea (1,2). Since then, several randomized hospi-
tal- and community-based trials have consistently 
demonstrated the efficacy of zinc treatment for 
acute or persistent diarrhoea in children aged less 
than five years (under-five children) (3-6). Pooled 
analyses of published data demonstrate that zinc 
reduces the duration and severity of acute diarrhoea 
and the likelihood of a prolonged episode (7,8). Re-
sults from these efficacy trials were then replicated 
by a community-based, effectiveness trial of zinc 
treatment for acute childhood diarrhoea carried 
out in the ICDDR,B rural field site in Matlab. In 
this trial in which children received daily zinc treat-
ment for each episode of diarrhoea, children in the 
zinc intervention group had a shorter duration of 
illness, a reduced likelihood of a repeat episode of 
diarrhoea, and non-injury mortality. The reduction 
in mortality was very substantial (50%) (9). This 
study  and  several  more-cited  investigations  were 
carried out by scientists at ICDDR,B who continue 
to study the effects of zinc on diarrhoeal and other 
illnesses, most notably childhood pneumonia.
The World Health Organization (WHO) has esti-
mated the global annual burden of mortality attrib-
utable to zinc deficiency to be 750,000 deaths (10). 
It is anticipated that over one-half of these deaths 
could be averted through the successful application 
of zinc as a treatment for childhood diarrhoea (11). 
Given this potential reduction in mortality and the 
strength of the evidence at hand in support of zinc 
treatment, the WHO/United Nations Children’s 
Fund (UNICEF) issued, in May 2004, a joint state-
ment on updated guidelines for the management 
of childhood diarrhoea (12). This includes the rec-
ommendation that all under-five children be treat-
ed with zinc (20 mg/day if age is 6-59 months and Larson CP et al. Zinc treatment to under-five children
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10 mg/day if age is less than six months) for 10-14 
days. This recommendation is now a policy of the 
Ministry of Health and Family Welfare, Govern-
ment of Bangladesh, with a slight modification to 
include children starting at two months of age.
are especially prone to zinc deficiency because of 
poor dietary quality and increased faecal loss of 
zinc due to repeated gastrointestinal infections 
(8). Children with modest levels of chronic zinc 
deficiency do not manifest any observable clinical 
signs that would alert clinicians to its presence, thus 
making it a hidden disorder. Bangladesh has one of 
the highest prevalence levels in the world, affecting 
over 50% of all under-five children (15). 
Being a micronutrient component in many metal-
lo-enzymes and poly-ribosomes involved in cel-
lular function, zinc supports normal growth and 
development during pregnancy, childhood, and 
adolescence (16). It is essential for metabolism, cel-
lular growth, and immune function (17). Despite its 
essential role, overt clinical syndromes associa- 
ted with zinc deficiency in humans are rare.  
The first published description of clinically-evi-
dent zinc deficiency due to nutritional causes in 
otherwise normal humans was documented in the 
Middle East in the 1960s among adolescent boys, 
characterized by stunted growth and delayed sexu-
al maturation that were reversible with supplemen-
tation of zinc (18). One well-known zinc-deficiency 
disorder with overt clinical signs is acrodermatitis 
enteropathica, a genetic autosomal recessive dis-
ease with an inborn defect in metabolism that re-
sults in reduced intestinal absorption of zinc (19). 
The discovery of this genetic disorder and its rapid 
resolution when treated with zinc alerted clinicians 
to the potential impact of zinc as a clinical defi-
ciency disorder in humans. Not long after this dis-
covery, zinc deficiency was also found to occur in 
adult patients on total parenteral nutrition, which 
was attributable to the failure to add zinc in the in-
travenous infusates (20,21). These individuals suf-
fered from loss of memory, skin disorders, loss of 
taste, and increased susceptibility to infection—all 
of which disappeared when zinc was added.  
It is now well-known that mild-to-moderate zinc 
deficiency due to inadequate dietary intake is pre-
valent in all parts of the world, with higher pre-
valence in developing countries, due primarily to 
low intake of zinc from animal sources, high dietary 
phytate content, and inadequate food intake (13).  
ZINC, INFECTION, AND IMMUNITY
Closely linked to these effects is the important role 
it plays in maintaining normal immune function. 
Results  of  studies  have  suggested  that  zinc  defi-
ciency impairs cell regeneration, epithelial barrier 
functions, and linear growth (22). Zinc deficiency 
•	 Zinc	deficiency	is	estimated	to	be	related	to	
750,000 deaths annually.
•	 WHO	and	UNICEF	now	recommend	10-14	
days of zinc treatment for under-five children 
with each diarrhoea illness.
•	 Zinc	treatment	is	inexpensive,	safe,	and	easy.
•	 Zinc	 treatment	 shortens	 the	 diarrhoea	 epi-
sode, reduces the risk of episode being persist-
ent, and reduces the risk of future diarrhoea 
or pneumonia.
•	 Zinc	treatment	reduces	overall	mortality.
•	 Now	the	task	is	to	provide	zinc	treatment	to	
every child in Bangladesh with each episode 
of diarrhoea.
This paper summarizes our understanding of zinc 
deficiency in children, its relationship with child-
hood morbidity and mortality, the strategies that 
have been tested to supplement zinc, and the bene-
fits of these interventions. This is followed by a dis-
cussion of future research priorities and their appli-
cability to health policy and planning.
ZINC DEFICIENCY IN EARLY CHILDHOOD
Population-based estimates of the occurrence of 
zinc deficiency in young children are hindered by 
the lack of an accurate measure of zinc status. Cur-
rent estimates are based upon one or a combina-
tion of zinc-deficiency indicator(s). These include 
rates of stunting, the amount of zinc in national 
food supplies, serum zinc levels, and histories of di-
etary intake.  
Despite the limitations in accurately estimating zinc 
levels, it is now recognized that mild-to-moderate 
zinc deficiency due to inadequate dietary intake is 
prevalent in all parts of the world. The higher prev-
alence of zinc deficiency in developing countries 
is due primarily to low intake of zinc from animal 
sources, high dietary phytate content (that limits 
the bioavailability of zinc), and inadequate food in-
take (13). A population-level analysis from national 
food-balance sheets has estimated that 21% of the 
world population is at risk of inadequate zinc in-
take; however, the percentages are much higher in 
least-developed countries (14,15). These children Larson CP et al. Zinc treatment to under-five children
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also impairs immunocompetence with reduced 
cell-mediated immune responses, decreased T-lym-
phocytes, abnormal T-helper and/or suppressor 
functions, impaired macrophage function, and 
reduced killer cells and antibody-dependent cyto-
toxicity (23,24). The levels of complement in blood 
increases with supplementation of zinc in children 
with acute diarrhoea (Qadri F. Personal communi-
cation, 2006). Zinc levels also modulate the func-
tion of monocytes, macrophages, and neutrophils 
polymorphs and in the release of reactive free radi-
cals from phagocytes (23). These impairments in 
immune function occur even with modest levels of 
zinc deficiency. 
The possible mechanisms of the effect of zinc treat-
ment on the duration and severity of diarrhoea 
include improved absorption of water and electro-
lytes by the intestines (25-27), regeneration of gut 
epithelium (28-31), increased levels of enterocyte 
brush-border enzymes (32,33), and enhanced im-
munologic mechanisms for the clearance of infec-
tion. Supplementation of zinc improves immunity 
(34-36) and may, hence, promote rapid clearance 
of diarrhoeal pathogens from the intestine.  
Innate immunity is the body’s first line of defence 
to pathogens, and its functions are also disturbed by 
altered zinc levels. Natural killer cell numbers and 
function are dependent on normal levels of serum 
zinc (37). These levels also modulate the function 
of monocytes, macrophages, and neutrophils (23). 
Zinc is also required for the development and acti-
vation of T-lymphocytes. When zinc supplements 
are given to individuals having low levels of zinc, 
the numbers of T-cell lymphocytes circulating in 
the blood increase, and the ability of lymphocytes 
to fight against infection improves.  
ZINC DEFICIENCY AND MORBIDITY
Given the numerous biologic functions dependent 
upon normal levels of zinc, particularly immunity, 
it is not surprising to find that zinc deficiency is 
associated with numerous infectious illnesses, but 
the link between diarrhoea and zinc is especially 
well-established. Diarrhoea leads to loss of zinc 
and abnormalities of zinc metabolism. Substantial 
amounts of zinc are lost during acute diarrhoea: 
daily losses of zinc during diarrhoea can be as high 
as 160 µg/kg per day in children (38).
How important are marginal deficiencies in zinc? 
Clinical and field studies have consistently ob-
served an association between zinc deficiency and 
morbidity due to infectious diseases, particularly 
diarrhoea in early childhood (39-41). Marginal zinc 
deficiency is associated with about a 50% increased 
risk and number of days with diarrhoea. However, 
zinc deficiency results in higher rates of other in-
fectious diseases as well, including skin infections, 
respiratory infections, malaria, and delayed wound 
healing (17). Overall, zinc-deficient children are at 
a three-fold increased risk of an acute respiratory 
infection (40,41).  
EFFECTS OF ZINC SUPPLEMENTATION
The recommended dietary allowance (RDA) for 
infants aged 0-6 month(s) is 2.0 mg, and it is 3.0 
mg per day for young children aged 7-36 months 
(42). However, the amount of zinc needed in 
young infants to maintain a positive zinc balance 
in areas with a high prevalence of zinc deficiency 
is unknown. The majority of published results of 
efficacy trials of zinc treatment have tested doses 
ranging from 10 mg (infants) to 20 mg (under-five 
children) of elemental zinc per day, a dosage that is 
safe in these children. Doses of up to 70 mg twice a 
week have been provided without an any toxic ef-
fect or clinically-significant copper deficiency (43). 
Several controlled zinc-treatment trials over the 
past decade have demonstrated the beneficial role 
of zinc in the prevention and treatment of diar-
rhoea (1-3,6-9,44,45). Meta-analyses of these trials 
estimate that children, aged three months to five 
years, who receive zinc for the treatment of a diar-
rhoeal illness (20 mg/day for 10 days), recover faster 
and experience a 30% reduction in the likelihood of 
developing prolonged diarrhoea. Over 3-6 months 
following treatment, there is a 30% decreased like-
lihood of a subsequent episode and an estimated 
50% reduction in non-injury mortality (8,9,46,47).
Zinc has also been demonstrated to be effective as 
a daily supplement in the prevention of diarrhoeal 
illnesses.  A  community-based,  double-blind,  ran-
domized trial in India observed a 26% lower in-
cidence of diarrhoea and a 35% lower prevalence 
in  children  who  received  daily  supplementation 
of zinc for six months (48). A trial of zinc supple-
mentation (10 mg/day) in growth-retarded Viet-
namese children observed a 71% lower incidence 
of diarrhoea (49). A similar trial in Mexico found 
a 36% lower incidence of diarrhoeal episodes in 
zinc-supplemented (20 mg/day) children (50). It 
has also been observed that supplementation of 
zinc reduces the incidence of persistent diarrhoea 
in zinc-deficient children and reduces the risk of 
dysentery (51). A report from Guatemala also in-
dicated that supplementation of zinc reduces the Larson CP et al. Zinc treatment to under-five children
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incidence of all types of diarrhoea (52). Studies in 
Bangladesh also demonstrated that supplementa-
tion of zinc to children with diarrhoea improves 
their growth (53).  
The table provides a summary of several recently-
published studies examining the preventive effects 
of zinc provided either as a treatment or as a daily 
supplement. The table shows that either strategy 
appears to provide protection against the future oc-
currence of acute diarrhoea, and the protection lasts 
for 3-6 months following treatment or cessation of 
supplementation. The treatment also decreases the 
likelihood that an acute episode of diarrhoea will 
progress on to a prolonged (>7 days) or persistent 
(>14 days) episode of diarrhoea. 
ZINC SAFETY
Acute zinc toxicity due to excess administration 
(225-450 mg of zinc) includes gastrointestinal 
symptoms, such as nausea, vomiting, epigastric 
pain, abdominal cramps, and bloody diarrhoea (58). 
Recent randomized clinical trials among adults and 
adolescents with acne, anorexia nervosa, macular 
degeneration, common cold, and tuberculosis, 
using elemental zinc in the dose range of 50-100 
mg/day, frequently reported nausea and vomiting 
as side-effects (59-61).
Transient vomiting or nausea among adults at doses 
of 50 mg/day or higher are well-known side-effects 
of zinc (62,63). Whether similar effects at the lower 
Table. Summary of studies testing for preventive impact of zinc as a treatment or supplement
Study Setting Zinc dose Results (reduction effect)
Roy SK, 1999 (53)         Bangladesh, hos-
pital-based
20 mg/day x 14 
days of treatment
14% ACD
58% ALRI
Baqui AH, 2002 (9)    Bangladesh, com-
munity-based
20 mg/day x 14 
days of treatment
15% ACD 
19% ACD hospital, 
51% non-injury mortality
Sazawal S, 1996 (51)     India  10 mg/day 
supplement x 6 
months
21% PCD
14% ACD
Rosado JL, 1997 (50)     Mexico 20 mg/day
supplement x 12 
months
20% ACD
Ruel MT, 1997 (52)      Guatemala 10 mg/day 
supplement x 7 
months
22% ACD
67% PCD
Ruz M, 1997 (54)          Chile 10 mg/day 
supplement x 14 
months  
No effect on morbidity
Sazawal S, 1997 (48)            India 10 mg/day
supplement x 6 
months
17% in ACD (effect limi-
ted to subjects aged >12 
months)
Sazawal S, 1998 (55) India 10 mg/day
supplement x 17 
weeks
45% ALRI
Bhandari N, 2002 (56,57) India 10-20 mg/day 
supplement x 4 
months     
12% ACD
31% PCD
25% ALRI
ACD=Acute childhood diarrhoea; ALRI=Acute lower respiratory infection; PCD=Persistent child-
hood diarrhoeaLarson CP et al. Zinc treatment to under-five children
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dose of 10-20 mg/day will be observed in children 
is unclear. Strand reported a nearly two-fold in-
crease in vomiting when treating Nepalese children 
with 15-30 mg/day (6). Whether this was due to a 
direct side-effect of zinc or due to inadequate mask-
ing of the metallic taste of zinc could not be dif-
ferentiated. Other trials, including the effectiveness 
trial of Baqui et al., did not report increased risks of 
vomiting (9). In none of the cited studies was the 
increased risk of vomiting linked to adverse serious 
clinical outcomes. 
To document if zinc does increase vomiting in chil-
dren acutely ill with gastrointestinal illness, a ran-
domized, double-blind, placebo-controlled trial was 
carried out in the short-stay unit of the ICDDR,B 
hospital and an adjacent outpatient clinic (64). 
Many children had vomiting as part of their ill-
ness, but the concern was that zinc might increase 
the rate and/or severity of vomiting. Results of this 
study showed that children who received the dis-
persible zinc tablet formulation in a dose of 20 mg 
had a 14% increased risk of vomiting attributable 
to zinc following the first treatment dose. This is 
equivalent to one additional vomiting episode for 
every seventh child treated. The vomiting does not 
occur immediately after administration, but about 
10 minutes later and is transient in nature, occur-
ring only once in over 90% of children. Thus, it 
does seem that treatment with zinc does increase 
the rate of vomiting somewhat in children who are 
acutely ill with diarrhoea, but the increase is slight 
and transient. Vomiting has not been a problem in 
children who are not acutely ill with gastrointesti-
nal diseases.
ZINC ADMINISTRATION ALONE OR 
IN COMBINATION WITH OTHER 
MICRONUTRIENTS
The clear benefits have raised questions about the 
most appropriate use of zinc. Should it be used as 
a single therapy, or should it be combined with 
other minerals and vitamins, especially when used 
in a dietary supplement or a food fortificant? An-
swering these questions will require additional re-
search to validate the most effective products for 
children, especially for long-term use. However, for 
use in treating children with diarrhoea, the safety 
and benefits of zinc alone are clearly defined, and 
recommendations for its use are compelling. We, 
thus, feel that programmes to implement the re-
commendations of WHO/UNICEF need to be 
scaled up as rapidly as possible, even while research 
continues to identify the best products for dietary 
supplementation or fortification. It should be not-
ed that recent efforts to combine zinc with iron/
folic acid in East Africa, an area with high rates of 
malaria, found higher rates of hospitalization and 
mortality in children who received the combined 
supplement (65). Such combinations may, thus, 
need to be examined more closely to assure free-
dom from adverse events.
SCALING UP ZINC AS A TREATMENT 
FOR CHILDHOOD DIARRHOEA
The greatest challenge facing health researchers, 
practitioners, and funding agencies is how to trans-
late the proven effectiveness of zinc as a treatment 
into action that will benefit the lives of young 
children, particularly those living in conditions 
of chronic poverty and malnutrition. In 2003, 
ICDDR,B launched the Scaling Up Zinc for Young 
Children (SUZY) Project with the aim of setting 
Bangladesh on the path to providing all under-five 
children with diarrhoea with zinc treatment, irres-
pective of gender, income, or geographic location. 
To attain this goal, the SUZY Project has been or-
ganized around five key activities: (a) registration, 
production, and distribution of zinc tablet, (b) 
promotion among healthcare providers and mass 
media campaign, (c) training of professionals and 
introduction of zinc treatment into public, private 
and NGO delivery systems, (d) formative and op-
erations research in support of scaling up, and (e) 
knowledge transfer from Project findings.  
With regard to registration and production, the 
Project decided to pursue the scaling up of a dis-
persible, 20-mg zinc sulphate tablet (which is now 
known as ‘Baby Zinc’ in Bangladesh), as recom-
mended by WHO. The tablet is placed in a spoon 
or a small cup and water added which leads it to 
disperse into a sweet, vanilla-flavoured syrup that 
masks the taste of zinc. The treatment is packaged 
in a 10-tablet blister pack, and caretakers are in-
structed to give one tablet per day for 10 days. It 
was not known at the time of launching whether 
young Bangladeshi children would find the tablet 
formulation acceptable, whether caretakers could 
correctly adhere to treatment instructions. This was 
studied in rural and urban settings, with findings 
indicating that the formulation was highly accept-
able and that treatment instructions were easily fol-
lowed. Ninety-eight percent of caretakers prepared 
the syrup correctly; over 90% perceived that their 
children found the taste to be acceptable, and the 
tablets were given, on average, for eight days (66). 
There were also concerns regarding side-effects as-Larson CP et al. Zinc treatment to under-five children
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sociated with the formulation. As already described, 
it was found that the formulation is associated with 
a transient increase in the risk of vomiting, but with 
no adverse clinical consequences (64).
Formative studies were undertaken that involved 
caretakers of children with an active case of diar-
rhoea, healthcare providers (licensed and unli-
censed), drug vendors, and medical representatives 
(drug salesmen). A recent baseline survey con-
ducted throughout Bangladesh showed that most 
(>90%) consultations of healthcare providers for 
a childhood diarrhoea episode involve the private 
sector (67). This survey also confirmed the dispari-
ties  in  care  received,  favouring  households  with 
higher wealth, and those living in urban settings. 
This has led the SUZY Project to develop a promo-
tion  strategy  that  emphasizes  awareness-building 
in the private sector, but also sensitization and 
training programmes for the government (public) 
and NGO sectors. The formative caretaker and pro-
vider interviews have led to the development of a 
frequently-asked databank. Some more frequently-
asked questions and responses are found in the Ap-
pendix.
CURRENT ISSUES AND FUTURE 
RESEARCH PRIORITIES
Healthcare-delivery systems
To reach all children with diarrhoea, zinc treatment 
will need to be introduced and sustained within 
the public, private and NGO service-delivery sys-
tems. Each of these systems has its unique set of 
strengths and weaknesses that must be taken into 
account in the planning stages. Unanswered ques-
tions include whether or not zinc treatment can 
be introduced through community health workers 
or depot-holders, the impact of over-the-counter 
availability of zinc on the use of health services, 
and the misuse of zinc for untested disorders, such 
as acute respiratory tract infections, poor growth, 
and loss of appetite.
Financing
As a preventive measure, treatment of childhood 
diarrhoea with zinc has been estimated to be one 
of the most cost-effective interventions available.   
Nonetheless, because of the shear frequency of 
childhood diarrhoea, the costs either at the house-
hold level or those assumed by the public or pri-
vate sector could be substantial. It remains to be 
demonstrated what the longer-term impact of a 
successful scaling-up campaign will be. It is reason-
able to assume that an initial investment in zinc 
treatment will eventually lead to deceased expen-
diture on other drugs, particularly antibiotics, and 
the costs avoided by preventing episodes of future 
illness. Until these assumptions are verified and 
appropriate information is disseminated, decision-
makers will be reticent to commit public or other 
subsidized financial resources, e.g. NGO clinics. A 
further constraint faced by the private sector, par-
ticularly the pharmaceutical industry, is the current 
lack of sound data upon which to estimate demand 
and pricing of product.
Combining zinc and iron 
Iron and zinc deficiencies commonly coincide 
in early childhood. The obvious conclusion is to 
treat both the conditions simultaneously. It is not 
yet clear whether or not this combined approach 
should be made a public-health policy; in fact, 
there is now concern about using iron routinely in 
malaria-endemic areas. It is known that, in chil-
dren receiving zinc therapy, levels of serum iron are 
adversely affected. Evidence is also emerging that, 
while children are receiving iron supplementation, 
the effects of zinc supplementation in terms of re-
duced morbidity are cancelled out—at least in ar-
eas with high rates of malaria. It will, therefore, be 
important to test alternative supplementation and 
zinc-treatment strategies and confirm these results 
in the desired beneficial effects prior to establishing 
policies in favour of combined supplementation. 
Finally, it may be the case that combined therapies 
will have a differential impact based upon the nu-
tritional status of a child and the severity of his/her 
micronutrient status. This requires further study.
Impact on diarrhoea-management practices and 
use of drugs: As zinc treatment is introduced, what 
will happen to existing diarrhoea-management 
practices? Will zinc be added to existing treatments, 
such as ORS (desired) and antibiotics (not desired)? 
Will providers and drug vendors view zinc as an op-
portunity or as a threat, and for what reasons? Giv-
en the first national scaling up of zinc is occurring 
in Bangladesh, it is difficult to predict how this will 
influence current practices, thus the importance of 
having in place the capacity to monitor for the po-
tential desired and undesired changes in manage-
ment practices.
Home management of childhood diarrhoea
Caretakers in Bangladesh lead the world in the use 
of ORS. We need to build upon this success as 
zinc treatment in childhood diarrhoea is intro-
duced through mass media and promotion. Given Larson CP et al. Zinc treatment to under-five children
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that zinc will be available over-the-counter in 
stores  without  prescription,  caretakers  will  have 
easy access to it. The challenge will be to develop 
and confirm the effectiveness of public education 
that aims at improving home-management prac-
tices.
SUMMARY
Zinc is one of the most important new health inter-
ventions which is only now beginning to be scaled 
up in Bangladesh and will, hopefully, be soon in-
troduced in other countries. It has the potential to 
be one of the most cost-effective health interven-
tions for child survival as were ORS and measles 
vaccine. When studies first started, it was thought 
that it might be a way of improving treatment of 
diarrhoea somewhat, but it has turned out to be a 
real life-saver.
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APPENDIX
Frequently-asked Questions about Use of Zinc in Treating Children with Diarrhoea
1.  What is zinc? What does it do? Zinc is a mineral, not a vitamin. It is an essential micronutrient 
found in almost every cell in the body. It stimulates the activity of approximately 100 enzymes that 
help in multiple biological functions of the human body. Importantly, it supports a healthy im-
mune system and is needed for wound healing. 
2.  What are the natural sources of zinc? The natural sources of zinc are: red meat, poultry, beans, nuts, 
whole grain, dairy products, and certain sea-foods, such as oysters.
3.  Can the zinc tablet be given to a child without consulting a doctor? Yes, it is not necessary to consult 
a doctor to give zinc. Zinc should be given to any child with diarrhoea regardless of the type of diar-
rhoea. For children who exhibit severe symptoms, such as vomiting or dehydration, it is important 
to consult a healthcare provider first.  
4.  What is the dose and duration of zinc treatment in diarrhoea? Is there any side-effect of the above 
dose? The treatment of diarrhoea involves a 20-mg tablet once per day for 10 days. The 20-mg dose 
is perfect for the children aged from 6 months to <5 years. The only potential side-effect is transient 
vomiting.
5.  Why tablets and not syrup? There are several zinc syrups available in the market, and these are as 
effective as the tablets during diarrhoea. The tablets are preferred because: 
 These are less costly
 It is easier to give the correct dose and keep track of the number of days given
 Tablets are easier to distribute and store 
6.  Can zinc be given by mixing it with juice, ORS, breastmilk, or any other liquids? The zinc tablet is 
meant to be dissolved in water. However, a spoonful of ORS or breast milk can replace a spoonful of 
water. Other fluids are not recommended. 
7.  Should a child be given another course of zinc treatment if he/she experiences a second episode 
of diarrhoea? Yes, all episodes of diarrhoea should be treated with zinc. Even if a child has recently 
completed a full course of zinc treatment, it is still safe to give a second dose. 
8.  Will zinc work for children above five years of age as well as it does for children aged below five 
years? Probably, it would. However, there is no scientific evidence demonstrating the effectiveness 
of zinc as a treatment for diarrhoea in children aged over five years. In addition, older children are 
less susceptible to the more severe-effects of diarrhoea, so they may not benefit to the same degree. 
9.  Can diarrhoea be treated with zinc only? Acute childhood diarrhoea should be treated with ORS 
AND zinc. In children with bloody diarrhoea or suspected cholera, an antibiotic may also be re-
quired.  Zinc is not an alternative for ORS.
10. Can zinc be given to an exclusively-breastfed child? Yes, to treat diarrhoea, zinc can be given to an 
exclusively-breastfed child.